Bioline hiv1 2 3.0 rapid test

After eligibility was confirmed, informed consent was obtained and a structured questionnaire was administered by a trained interviewer. The questionnaire examined demographic factors in addition to drug and alcohol use, sexual and injection risk behaviors (in the previous six months), mental health, and participation in harm reduction and treatment programs.
Each participant received counseling and testing for HIV and HCV. HIV antibody and HCV antibody testing were conducted at the laboratory of the Hai Phong Provincial AIDS Committee, using commercially available assays. HIV testing relied on Determine™ HIV-1/2 (Alere™, Waltham, USA) rapid test. HIV confirmation was done using Bioline HIV1/2 3.0 rapid test (Standard Diagnostics Inc., Gyeonggi-do, Republic of Korea) plus the VIKIA® HIV1/2 (Marcy l’étoile, Lyon, France). HCV serology was done using SD Bioline HCV rapid test (Standard Diagnostics Inc., Gyeonggi-do, Republic of Korea).
Participants were compensated VND 150,000 (approximately US $7.50) plus VND 50,000 (approximately USD $2.50) for each PWID they successfully recruited, and received an additional VND 50,000 for transportation to return to the study site for HIV and HCV test results.

The participants included were part of the DRIVE study¹⁷ which between 2016–2018 recruited a cohort of PWID in Hai Phong Vietnam using respondent driven sampling. We enrolled all HIV positive and a sample of HIV negative PWID into a cohort to monitor HIV incidence, associated risk behaviors, and use of intervention and support services.
Eligible participants had to be injecting drugs, at least 18 years of age, and capable of giving informed consent. Injection drug use was verified through the examination of injection marks and urinalysis for heroin and/or methamphetamine use.
Each participant received counseling and testing for HIV. HIV antibody testing was conducted using Bioline HIV1/2 3.0 rapid test (Standard Diagnostics Inc. Gyeonggi-do, Republic of Korea). Confirmation testing was conducted using Determine^™ HIV-1/2 (Alere^™, Waltham, MA, USA) plus the VIKIA^® HIV1/2 (Marcy l’Étoile, Lyon, France). HIV viral load was measured at the national reference laboratory (NIHE, Hanoi) using the COBAS Taqman HIV-1 test v2.0 (Roche diagnostics, Hanoi, Vietnam).
We restricted our sample to visits where PWID reported receiving ART, had non missing self-report methamphetamine use and ART adherence scores and HIV viral load measurements from laboratory tests.